The 2026 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was successfully held in Shanghai on June 5, 2026. The event was jointly organized by Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the National Clinical Research Center for Hematologic Diseases-Peking University, Institute of Hematology and EBMT Shanghai Office. It was co-hosted by Shanghai Guangci Translational Medical Research Development Foundation and the MedScience, with the support of the Boxiao Foundation under the aegis of the Fondation de France.
At the opening ceremony, Professor Chen Saijuan , Member of Chinese Academy of Engineering and foreign Corresponding Member of the French National Academy of Medicine, emphasized that China-Europe cooperation on haematology had evolved from academic exchanges to a new stage of collaborative innovation. Through breakthroughs in research on the molecular mechanism and target therapy for Acute Promyelocytic Leukaemia (APL), she illustrated that international collaboration was a key driver for medical innovation and better patient outcomes. Professor Huang Xiaojun, Member of Chinese Academy of Engineering and foreign Corresponding Member of the French National Academy of Medicine, stated that after four years and four host cities the forum had become a vital bridge connecting hematology communities in China and Europe, laying a solid foundation for further exchanges and cooperation. Professor Ibrahim Yakoub-Agha, President of EBMT, noted that the forum served as an important platform for China-Europe exchanges in hematology, hematopoietic stem cell transplantation and advancing cellular therapy. He acknowledged the continuous support from Chinese members on the EBMT cooperative system and pointed out that a growing number of Chinese members had been deeply integrated into EBMT research network, which reflecting the breadth and depth of bilateral cooperation. He also expressed gratitude to the Boxiao Foundation for its long-standing support of China-Europe cooperation and exchange. Professor Hu Yu, president of the Chinese Association of Hematology, acknowledged the fruitful achievements of long-term academic and research cooperation between EBMT and the Hematology Branch of Chinese Medical Association.
Following the opening ceremony, the EBMT New Member Certificate Awarding Ceremony was held, presided over by Professor Norbert Claude Gorin, former President of the EBMT Global Committee. Professor Ibrahim Yakoub-Agha (President of EBMT) and Professor Zhang Xiaohui (President-Elect of the Chinese Association of Hematology) jointly presented membership certificates to the new Chinese centre members.
Throughout the forum, experts from China and Europe engaged in in-depth discussions on six sessions: Translational Medicine, Leukemia, Lymphoma, Cellular Therapy, Hematopoietic Stem Cell Transplantation, and New Technologies and Methods for Hematological Diseases. Especially, Professor Chen Zhu, member of the Chinese Academy of Sciences and foreign Member of the French Academy of Sciences, delivered a keynote address. In his address, he reviewed achievements in the prevention and treatment of hematological malignancies as well as healthcare system reform in China, and set a target of reducing PMR-NCD4 by 30% by Year 2030. He also highlighted the vital role of EBMT cooperation in advancing international collaborative innovation, which won enthusiastic responses and high praise from experts from both China and Europe. The forum covered a wide range of topics from fundamental mechanism research to precision diagnosis and treatment of diseases, from innovation in therapeutic approaches to exploration of cutting-edge technologies. The participating experts comprehensively presented an innovative vision of hematology evolving from laboratory discoveries into clinical translation. This event not only showed a collection of academic achievements, but also the common vision of hematology communities between China and Europe to advance innovative breakthroughs and jointly improve patient outcomes.
2026年中欧血液与骨髓移植和细胞治疗科学会议在沪成功举办
2026年6月5日，由上海交通大学医学院附属瑞金医院、国家血液系统疾病临床医学研究中心-北京大学血液病研究所、欧洲血液和骨髓移植协会基金会（荷兰）上海代表处共同主办，上海广慈转化医学研究发展基金会、《医学科学（英文）》期刊联合承办，法国博效基金会支持的“2026年中欧血液与骨髓移植和细胞治疗科学会议”在上海圆满召开。
大会开幕式致辞中，中国工程院院士、法国国家医学科学院外藉院士陈赛娟教授强调，中欧血液学合作已从学术交流迈向协同创新的新阶段。她以急性早幼粒细胞白血病（APL）分子机制研究和靶向治疗的突破为例，阐明国际合作是推动医学创新和改善患者预后的重要动力。中国工程院院士、法国国家医学科学院外藉院士黄晓军教授表示，本论坛历经四载春秋、四城接力，已成为连接中欧血液学界的重要桥梁，为双方深化交流合作奠定了坚实基础。EBMT主席Ibrahim Yakoub-Agha教授则强调，本次论坛已成为中欧血液学、造血干细胞移植及先进细胞治疗领域的重要交流平台。他肯定中国中心对EBMT合作体系的持续支持，并指出越来越多中国中心深度融入EBMT研究网络，体现了双方合作的广度与深度，并感谢博效基金会对中欧交流平台构建与合作作出的持续支持和努力。中华医学会血液学分会主任委员胡豫教授肯定了中华医学会血液学分会与EBMT长期合作，在学术交流和科研合作方面取得丰硕成果。
开幕式后举行了EBMT中国新会员授证仪式，由EBMT全球委员会前主席Norbert Claude Gorin教授主持，EBMT主席Ibrahim Yakoub-Agha 、中华医学会血液学分会候任主委张晓辉教授一起为新加入的单位颁发会员证书。
会议期间，中欧顶尖学者围绕转化医学、白血病、淋巴瘤、细胞治疗、造血干细胞移植及血液疾病的新技术新方法六大主题展开深入交流。。尤其是中国科学院院士、法国科学院外藉院士陈竺教授的主旨发言，回顾了中国血液肿瘤防治与医药卫生体制改革成效，并提出到2030年将PMR-NCD4降低30%的行动目标，强调EBMT合作对推动国际协同创新的重要意义，引起中欧专家积极反响与极高评价。论坛从基础机制研究到疾病精准诊疗，从治疗模式革新到前沿技术探索，与会专家系统呈现了血液学领域从实验室发现到临床转化的创新图景。这不仅是一次学术成果的集中展示，更彰显了中欧血液学界携手推动创新突破、共促患者获益的共同愿景。